BCL2 and neoplasm: It has been reported that simultaneous administration of SAHA and TRAIL significantly upregulated the TRAIL death receptors DR4/DR5 and downregulated the anti-apoptotic members of the BCL-2 family in several tumor cell lines54, 55, 56, 57.